Walgreens is now stocking Narcan® nasal spray as part of its commitment to combat drug abuse

Narcan® Nasal Spray

DEERFIELD, Ill., 2017-Oct-27 — /EPR Retail News/ — As part of its comprehensive national plan to combat drug abuse, Walgreens is now stocking Narcan®, an FDA-approved nasal form of naloxone, in all of its more than 8,000 pharmacies nationwide.

The medication, administered by nasal spray, can be used in the event of an overdose to reverse the effects of opioid drugs, which include some prescription painkillers and heroin.

“By stocking Narcan in all our pharmacies, we are making it easier for families and caregivers to help their loved ones by having it on hand in case it is needed,” said Rick Gates, Walgreens group vice president of pharmacy. “As a pharmacy we are committed to making Narcan more accessible in the communities we serve.”

In addition, Walgreens is adopting Centers for Disease Control and Prevention (CDC) recommendations by educating patients about Narcan when they are dispensed a controlled substance greater than 50 morphine milligram equivalents (MME) and may be at risk of accidental overdose.

“This action is an important milestone and we applaud Walgreens initiatives to improve access to Narcan Nasal Spray in communities across the U.S.,” said Seamus Mulligan, Chief Executive Officer of Adapt Pharma, the manufacturer of Narcan Nasal Spray. “This effort, combined with the opportunity for patients and caregivers to obtain Narcan Nasal Spray without an individual prescription in 45 states, is critical in combating this crisis.”

In an effort to educate the public on use of naloxone, pharmaceutical wholesaler AmerisourceBergen has distributed Narcan demo devices at no cost to Walgreens pharmacists for use in instructing patients on how to administer the medication. Additional instructions include calling 911, as Narcan is not a substitute for medical care. Anyone who is administered the medication should seek immediate medical attention.

“At AmerisourceBergen, we strive to provide our customers the highest quality care and support so they can ultimately enhance the lives of patients in their communities,” said Robert Mauch, Executive Vice President & Group President, Pharmaceutical Distribution & Strategic Global Sourcing for AmerisourceBergen. “We recognize the important role we play in addressing the opioid epidemic, and our collaboration with Walgreens is another key milestone to supply our customers with access to lifesaving initiatives and emergency medications that can help keep individuals safe across the country.”

Last year Walgreens announced an effort to make naloxone available without requiring a prescription in states where regulations allow. The company now offers naloxone without requiring a prescription in 45 states and is eager and willing to work with the remaining states to make naloxone easier to obtain.

Walgreens has also collected more than 155 tons of unwanted medications through its safe medication disposal kiosks in 600 pharmacies across 45 states and Washington D.C. The kiosks allow individuals to safely and conveniently dispose of unwanted prescriptions, including controlled substances and over-the-counter medications, year-round at no cost.

About Walgreens
Walgreens (walgreens.com), one of the nation’s largest drugstore chains, is included in the Retail Pharmacy USA Division of Walgreens Boots Alliance, Inc. (NASDAQ: WBA), the first global pharmacy-led, health and wellbeing enterprise. More than 10 million customers interact with Walgreens each day in communities across America, using the most convenient, multichannel access to consumer goods and services and trusted, cost-effective pharmacy, health and wellness services and advice. Walgreens operates 8,175 drugstores with a presence in all 50 states, the District of Columbia, Puerto Rico and the U.S. Virgin Islands, along with its omnichannel business, Walgreens.com. Approximately 400 Walgreens stores offer Healthcare Clinic or other provider retail clinic services.

Contact(s)

Walgreens
Phil Caruso, 847-315-2936
philip.caruso@walgreens.com
http://news.walgreens.com
@WalgreensNews
facebook.com/Walgreens

CVS Health and Adapt Pharma to make opioid overdose-reversing drug NARCAN Nasal Spray affordable for patients without insurance at CVS Pharmacies

WOONSOCKET, R.I., 2016-Aug-02 — /EPR Retail News/ — CVS Health (NYSE: CVS) and Adapt Pharma (www.AdaptPharma.com) today announced a new partnership that will make the opioid overdose-reversing drug NARCAN (Naloxone HCl) Nasal Spray more affordable for patients without insurance at CVS Pharmacy locations. Through this partnership, CVS Pharmacy patients purchasing NARCAN Nasal Spray without insurance will receive a $35 discount coupon to purchase the medication, reducing the out-of-pocket cost by nearly 25 percent. NARCAN Nasal Spray is the first and only FDA-approved, ready-to-use nasal formulation of naloxone for the emergency treatment of opioid overdose. NARCAN Nasal Spray is available in a convenient box containing two units (each unit delivers a concentrated 4mg dose of active medication-naloxone hydrochloride- in a .1ml mist) for immediate use if the need arises.

“Having a ready-to-use dose of naloxone in a nasal spray device makes administration of this life-saving medication quick and easy for friends and families of loved ones struggling with addiction in an emergency overdose situation,” said Tom Davis, RPh, Vice President of Pharmacy Professional Practices at CVS Health. “Through this partnership with Adapt Pharma, NARCAN Nasal Spray will be more affordable for CVS Pharmacy patients who don’t have insurance. CVS Health is dedicated to helping communities address and prevent prescription drug abuse, which is why we have worked to increase access to the opioid overdose-reversal drug naloxone for patients. Using a physician’s standing order or collaborative practice agreement, we have eliminated the need for patients to obtain a prescription for naloxone in 31 states across the country.”

“This partnership is an important milestone in increasing access to FDA-approved naloxone formulations across U.S. communities. We are encouraged by the progress marked by CVS Pharmacy’s decision to improve affordability of NARCAN Nasal Spray, especially within states with standing orders, which allow patient access to this opioid overdose treatment without physician-written naloxone prescriptions,” saidSeamus Mulligan, Chairman and CEO of Adapt Pharma. “NARCAN Nasal Spray was designed with communities in mind, specifically breaking down barriers to a medication that has been proven, intuitive and ready-to-use by those most likely to encounter an overdose emergency, the friends, loved ones and caregivers of patients susceptible to opioid-related overdose. Now these community members will be able to access the first and only FDA-approved, ready-to-use nasal spray version of naloxone in thousands of CVS Pharmacy locations nationwide.”

CVS Health’s naloxone program establishes a standing order with a physician, which permits CVS Pharmacists to dispense naloxone to patients without an individual prescription. By August 2016, CVS Health will make this life-saving medication more accessible to CVS Pharmacy patients in 31 states: Arkansas, California, Colorado,Florida, Idaho, Indiana, Louisiana, Massachusetts, Minnesota, Mississippi, Montana,New Jersey, New York, North Dakota, Oregon, Pennsylvania, Rhode Island,Tennessee, Texas, Utah, Washington, Wisconsin, Connecticut, Kentucky, Maryland,North Carolina, New Hampshire, New Mexico, Ohio, Virginia and Vermont.

CVS Health’s commitment to help communities address and prevent drug abuse also includes drug abuse prevention education, outreach and access to safe medication disposal. Patients visiting CVS.com can find recently launched drug abuse prevention resources for themselves and their families. The company has also launched a community outreach program called Pharmacists Teach, which brings local pharmacists to high school health classes to talk to students about the dangers of drug abuse. More than 100,000 students have already been part of the program.

CVS Health has also joined with the Partnership for Drug-Free Kids for the Medication Disposal for Safer Communities Program, which has donated more than 600 drug disposal units to police departments around the country. The program gives members of the community a safe and environmentally friendly way to dispose of unwanted medication and has already collected more than 43 metric tons of prescription drugs. Members of the community can use a zip code locator at CVS.com to find the disposal unit closest to them.

About CVS Health
CVS Health (NYSE: CVS) is a pharmacy innovation company helping people on their path to better health. Through its more than 9,600 retail pharmacies, more than 1,100 walk-in medical clinics, a leading pharmacy benefits manager with nearly 80 million plan members, a dedicated senior pharmacy care business serving more than one million patients per year, and expanding specialty pharmacy services, the Company enables people, businesses and communities to manage health in more affordable and effective ways. This unique integrated model increases access to quality care, delivers better health outcomes and lowers overall health care costs. Find more information about how CVS Health is shaping the future of health at https://www.cvshealth.com.

Adapt Pharma
Adapt Pharma is a privately-held pharmaceutical company committed to positively impacting the lives of patients. Adapt Pharma’s strategy is to identify, evaluate, selectively acquire and enhance the value of late stage development, and FDA approved, pharmaceutical products. Adapt Pharma’s company headquarters is in Dublin, Ireland and its U.S. headquarters is in Radnor, Pennsylvania. For more information, please visit www.adaptpharma.com.

Media Contact:

Carolyn Castel
Corporate Communications
(401) 770-5717
Carolyn.Castel@CVSHealth.com

Adapt Pharma Media Contact:

Thom Duddy
Executive Director, Communications & Marketing
(484) 532-5470
Thomas.Duddy@adaptpharma.com

SOURCE: CVS Health